Neurocrine Biosciences, Inc. NBIX
Set alert
145.35 USD -0.75 -0.51%
At close · Nov 2
154.38 +9.03 +6.21%
After hours · Nov 2, 7:45 PM ET
143.75 Day range 147.57
122.14 52-week range 186.12
- YTD
- +2.48%
- 1 year
- +1.49%
- Open
- 145.70
- Prev close
- 146.10
- Mkt cap
- 14.77B
- Vol
- 2.02M
- Avg vol
- 1.24M
- EPS
- 6.82
- P/E
- 21.31
- Div yield
- 0.00%
More statistics
- Low
- 143.75
- High
- 147.57
- Forward P/E
- 12.14
- Beta
- 0.33
- Short ratio
- 4.41
- Inst. own
- 104.46%
- Dividend
- 0.00
- Ex-div date
- Dec 28, 1995
- Earnings
- Nov 2, 2026
- 50-d avg
- 146.63
- 200-d avg
- 147.38
- 1y target
- 206.22
5Y chart
Events in this range
- Jul 30, 2025Earnings: 1.06; estimate 0.98; surprise 8.16%
- Oct 28, 2025Earnings: 2.04; estimate 1.58; surprise 29.11%
- Feb 11, 2026Earnings: 1.88; estimate 1.8; surprise 4.44%
- May 5, 2026Earnings: 1.91; estimate 1.22; surprise 56.56%
- Jul 30, 2026Earnings: 2.85; estimate 1.85; surprise 54.05%
- Sep 3, 2026Rating: Citigroup · Buy → Buy
- Sep 8, 2026Rating: RBC Capital · Outperform → Outperform
- Sep 11, 2026Rating: Morgan Stanley · Equal-Weight → Equal-Weight
- Sep 29, 2026Rating: UBS · Buy → Buy
- Oct 12, 2026Rating: BMO Capital · Market Perform → Market Perform
- Oct 16, 2026Rating: Needham · Buy → Buy
- Nov 2, 2026Earnings: —; estimate 1.91; surprise —%
Signals (79)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 26, 2026 | 1 week ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| RSI: Overbought | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| SMA: Bullish | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Apr 6, 2026 | 7 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Feb 9, 2026 | 8 months ago |
| SMA: Bullish | Feb 2, 2026 | 9 months ago |
| SMA: Bearish | Jan 5, 2026 | 10 months ago |
| MACD: Sell Signal | Dec 22, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| SMA: Bearish | Nov 17, 2025 | 11 months ago |
| SMA: Bullish | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Sep 29, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | May 26, 2025 | 1 year ago |
| MACD: Buy Signal | May 12, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| RSI: Oversold | Apr 7, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 10, 2025 | 1 year ago |
| SMA: Bearish | Feb 3, 2025 | 1 year ago |
| SMA: Bearish | Feb 3, 2025 | 1 year ago |
| SMA: Bullish | Dec 16, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 25, 2024 | 1 year ago |
| SMA: Bullish | Nov 18, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Oct 28, 2024 | 2 years ago |
| SMA: Bearish | Aug 26, 2024 | 2 years ago |
| SMA: Bearish | Aug 26, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 26, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 15, 2024 | 2 years ago |
| SMA: Bullish | Jun 24, 2024 | 2 years ago |
| SMA: Bearish | May 27, 2024 | 2 years ago |
| SMA: Bullish | May 13, 2024 | 2 years ago |
| SMA: Bearish | May 6, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bearish | Apr 8, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 25, 2024 | 2 years ago |
| SMA: Bullish | Mar 4, 2024 | 2 years ago |
| SMA: Bearish | Feb 12, 2024 | 2 years ago |
| RSI: Overbought | Dec 18, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 27, 2023 | 2 years ago |
| SMA: Bullish | Nov 20, 2023 | 2 years ago |
| MACD: Sell Signal | Nov 13, 2023 | 2 years ago |
| SMA: Bearish | Nov 6, 2023 | 2 years ago |
| SMA: Bullish | Oct 30, 2023 | 3 years ago |
| SMA: Bearish | Oct 16, 2023 | 3 years ago |
| SMA: Bullish | Jul 24, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 10, 2023 | 3 years ago |
| SMA: Bearish | Jun 19, 2023 | 3 years ago |
| SMA: Bullish | Jun 12, 2023 | 3 years ago |
| SMA: Bearish | May 1, 2023 | 3 years ago |
| SMA: Bullish | Apr 3, 2023 | 3 years ago |
| SMA: Bearish | Jan 23, 2023 | 3 years ago |
| SMA: Bullish | Jan 16, 2023 | 3 years ago |
| SMA: Bearish | Jan 9, 2023 | 3 years ago |
| SMA: Bearish | Jan 9, 2023 | 3 years ago |
| SMA: Bullish | Jan 2, 2023 | 3 years ago |
| SMA: Bearish | Dec 26, 2022 | 3 years ago |
| MACD: Sell Signal | Dec 26, 2022 | 3 years ago |
| SMA: Bullish | Dec 19, 2022 | 3 years ago |
| SMA: Bearish | Dec 5, 2022 | 3 years ago |
| RSI: Overbought | Oct 31, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 1, 2022 | 4 years ago |
| SMA: Bearish | Jul 25, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 18, 2022 | 4 years ago |
| SMA: Bullish | May 23, 2022 | 4 years ago |
| SMA: Bearish | Apr 25, 2022 | 4 years ago |
| SMA: Bullish | Jan 31, 2022 | 4 years ago |
Key statistics
- Market cap
- 14.77B
- Enterprise value
- 14.92B
- Trailing P/E
- 21.31
- Forward P/E
- 12.14
- PEG ratio
- 0.30
- Price / sales
- 4.38
- Price / book
- 4.00
- EPS (TTM)
- 6.82
- Beta
- 0.33
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 20.91%
- Revenue (TTM)
- 3.37B
- Revenue growth
- 39.50%
- Free cash flow
- 638.24M
- Total cash
- 389.80M
- Total debt
- 461.60M
- Return on equity
- 22.09%
- Shares outstanding
- 101.65M
- Short % of float
- 8.24%
- 50-day average
- 146.63
- 200-day average
- 147.38
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 206.22 +41.9% upside
Now 145.35
- Target (low)
- 150.00
- Target (mean)
- 206.22
- Target (high)
- 253.00
Ratings (0m) 29 25 buy · 4 hold · 0 sell
- Strong buy4
- Buy21
- Hold4
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate 2.75.
Financials — quick view
NBIX Revenue — quarterly 959.00M
NBIX Net income — quarterly 144.40M
NBIX EPS — quarterly 1.43
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | 1.91 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 1.85 | 2.85 | +1.00 | +54.05% |
| May 5, 2026 | Mar 31, 2026 | 1.22 | 1.91 | +0.69 | +56.56% |
| Feb 11, 2026 | Dec 31, 2025 | 1.80 | 1.88 | +0.08 | +4.44% |
| Oct 28, 2025 | Sep 30, 2025 | 1.58 | 2.04 | +0.46 | +29.11% |
| Jul 30, 2025 | Jun 30, 2025 | 0.98 | 1.06 | +0.08 | +8.16% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2026 | Needham | reit | Buy | Buy |
| Oct 12, 2026 | BMO Capital | main | Market Perform | Market Perform |
| Sep 29, 2026 | UBS | main | Buy | Buy |
| Sep 11, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Sep 8, 2026 | RBC Capital | reit | Outperform | Outperform |
| Sep 3, 2026 | Citigroup | main | Buy | Buy |
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- neurocrine.com
News
- Neurocrine Biosciences Q3 Earnings Call Highlights
- Neurocrine Biosciences, Inc. (NBIX) Q3 2026 Earnings Call Transcript
- Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates
- Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to Say
- Neurocrine Biosciences Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B
- Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
- Neurocrine Biosciences Q3 Adj. EPS $3.29 Beats $1.91 Estimate, Sales $1.119B Beat $1.043B Estimate
- Here's Why Neurocrine Biosciences (NBIX) is a Strong Value Stock
- Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test
- Here's Why Neurocrine Biosciences (NBIX) is a Strong Growth Stock
Your note
Sign in to keep a note on NBIX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABERNETHY MATTHEW C | Chief Financial Officer | Sale | Sep 13, 2026 | 42,808 |
| BENEVICH ERIC S. | Officer | Stock Award(Grant) | Sep 10, 2026 | 67,297 |
| COOKE JULIE SMITH | Officer | Stock Award(Grant) | Sep 10, 2026 | 24,025 |
| GANO KYLE W | Chief Executive Officer | Stock Award(Grant) | Sep 10, 2026 | 154,728 |
| GORMAN KEVIN CHARLES | Director | Stock Award(Grant) | Sep 10, 2026 | 517,797 |
| LIPPOLDT DARIN M | Officer | Stock Award(Grant) | Sep 10, 2026 | 56,793 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 13.49% | 13,711,607 | 1.99B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 6.29% | 6,398,674 | 930.05M | Jun 29, 2026 |
| Dodge & Cox Inc. | 5.49% | 5,584,707 | 811.74M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.89% | 4,974,083 | 722.98M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.47% | 4,545,339 | 660.67M | Jun 29, 2026 |
| State Street Corporation | 4.31% | 4,385,598 | 637.45M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 3.90% | 3,964,000 | 576.17M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 3,620,760 | 526.28M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.14% | 3,193,267 | 464.14M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.27% | 2,304,996 | 335.03M | Jun 29, 2026 |
| J.P. Morgan Mutual Fd. Investment TRT-JPMorgan Growth Advantage Fd. | 1.34% | 1,358,475 | 197.45M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.31% | 1,329,829 | 193.29M | Jun 29, 2026 |